Intratumoral LAK cell and interleukin-2 therapy of human gliomas
- PMID: 2643685
- DOI: 10.3171/jns.1989.70.2.0175
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
Abstract
Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study, nine of whom were treated with 15 cycles of LAK cells (0.9 to 21.0 x 10(9) cells) and IL-2 (49 to 450 x 10(3) U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.
Similar articles
-
Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.Cancer Res. 1988 Sep 1;48(17):5011-6. Cancer Res. 1988. PMID: 3261631
-
[Adoptive immunotherapy in patients with malignant glioma].Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1930-2. Gan To Kagaku Ryoho. 1987. PMID: 3496052 Japanese.
-
[Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].No To Shinkei. 1988 Feb;40(2):119-25. No To Shinkei. 1988. PMID: 3259433 Japanese.
-
[LAK cells and cancer].Gan To Kagaku Ryoho. 1986 Dec;13(12):3327-33. Gan To Kagaku Ryoho. 1986. PMID: 3539024 Review. Japanese.
-
Adoptive therapies: quo vadis?Pathol Immunopathol Res. 1988;7(6):442-58. doi: 10.1159/000157074. Pathol Immunopathol Res. 1988. PMID: 3070530 Review.
Cited by
-
Biomarkers for glioma immunotherapy: the next generation.J Neurooncol. 2015 Jul;123(3):359-72. doi: 10.1007/s11060-015-1746-9. Epub 2015 Feb 28. J Neurooncol. 2015. PMID: 25724916 Free PMC article. Review.
-
Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection of the killer cells with the gamma-interferon gene.Jpn J Cancer Res. 1995 Jan;86(1):95-100. doi: 10.1111/j.1349-7006.1995.tb02993.x. Jpn J Cancer Res. 1995. PMID: 7537727 Free PMC article.
-
The value of EGFRvIII as the target for glioma vaccines.Am Soc Clin Oncol Educ Book. 2014:42-50. doi: 10.14694/EdBook_AM.2014.34.42. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857059 Free PMC article. Review.
-
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.PLoS One. 2013;8(1):e51805. doi: 10.1371/journal.pone.0051805. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326319 Free PMC article.
-
Immunotherapy for pediatric brain tumors: past and present.Neuro Oncol. 2019 Oct 9;21(10):1226-1238. doi: 10.1093/neuonc/noz077. Neuro Oncol. 2019. PMID: 31504801 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
